ERNA
Price
$1.46
Change
-$0.03 (-2.01%)
Updated
Aug 27, 12:38 PM (EDT)
Capitalization
10.97M
PEN
Price
$269.12
Change
+$3.11 (+1.17%)
Updated
Aug 27, 03:17 PM (EDT)
Capitalization
10.37B
63 days until earnings call
SLNO
Price
$68.89
Change
-$0.72 (-1.03%)
Updated
Aug 27, 02:25 PM (EDT)
Capitalization
3.7B
70 days until earnings call
Interact to see
Advertisement

ERNA or PEN or SLNO

Header iconERNA vs PEN vs SLNO Comparison
Open Charts ERNA vs PEN vs SLNOBanner chart's image
Ernexa Therapeutics
Price$1.46
Change-$0.03 (-2.01%)
Volume$101
Capitalization10.97M
Penumbra
Price$269.12
Change+$3.11 (+1.17%)
Volume$100
Capitalization10.37B
Soleno Therapeutics
Price$68.89
Change-$0.72 (-1.03%)
Volume$220
Capitalization3.7B
ERNA vs PEN vs SLNO Comparison Chart in %
Loading...
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
Interact to see
Advertisement
COMPARISON
Comparison
Aug 27, 2025
Stock price -- (ERNA: $1.49PEN: $266.00SLNO: $69.61)
Brand notoriety: ERNA, PEN and SLNO are all not notable
ERNA and SLNO are part of the Biotechnology industry, and PEN is in the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: ERNA: 17%, PEN: 138%, SLNO: 95%
Market capitalization -- PEN: $10.37B, SLNO: $3.7B, ERNA: $10.97M
$ERNA [@Biotechnology] is valued at $10.97M. $SLNO’s [@Biotechnology] market capitalization is $ $3.7B. $PEN [@Medical/Nursing Services] has a market capitalization of $ $10.37B. The market cap for tickers in the [@Biotechnology] industry ranges from $ $99.27B to $ $0. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $ $229.03B to $ $0. The average market capitalization across the [@Biotechnology] industry is $ $1.85B. The average market capitalization across the [@Medical/Nursing Services] industry is $ $5.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERNA’s FA Score shows that 1 FA rating(s) are green whilePEN’s FA Score has 0 green FA rating(s), and SLNO’s FA Score reflects 0 green FA rating(s).

  • ERNA’s FA Score: 1 green, 4 red.
  • PEN’s FA Score: 0 green, 5 red.
  • SLNO’s FA Score: 0 green, 5 red.
According to our system of comparison, PEN and SLNO are a better buy in the long-term than ERNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERNA’s TA Score shows that 4 TA indicator(s) are bullish while PEN’s TA Score has 7 bullish TA indicator(s), and SLNO’s TA Score reflects 4 bullish TA indicator(s).

  • ERNA’s TA Score: 4 bullish, 3 bearish.
  • PEN’s TA Score: 7 bullish, 4 bearish.
  • SLNO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, PEN is a better buy in the short-term than ERNA, which in turn is a better option than SLNO.

Price Growth

ERNA (@Biotechnology) experienced а -3.87% price change this week, while PEN (@Medical/Nursing Services) price change was +5.06% , and SLNO (@Biotechnology) price fluctuated +4.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.97%. For the same industry, the average monthly price growth was +13.89%, and the average quarterly price growth was +31.16%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +4.35%. For the same industry, the average monthly price growth was +3.95%, and the average quarterly price growth was +10.79%.

Reported Earning Dates

PEN is expected to report earnings on Oct 29, 2025.

SLNO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+3.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Medical/Nursing Services (+4.35% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PEN($10.4B) has a higher market cap than SLNO($3.7B) and ERNA($11M). SLNO YTD gains are higher at: 54.861 vs. PEN (12.009) and ERNA (-66.213). PEN has higher annual earnings (EBITDA): 194M vs. ERNA (-31.63M) and SLNO (-176.1M). PEN has more cash in the bank: 425M vs. SLNO (287M) and ERNA (4.32M). ERNA has less debt than SLNO and PEN: ERNA (593K) vs SLNO (52.8M) and PEN (221M). PEN has higher revenues than SLNO and ERNA: PEN (1.28B) vs SLNO (32.7M) and ERNA (488K).
ERNAPENSLNO
Capitalization11M10.4B3.7B
EBITDA-31.63M194M-176.1M
Gain YTD-66.21312.00954.861
P/E RatioN/A70.37N/A
Revenue488K1.28B32.7M
Total Cash4.32M425M287M
Total Debt593K221M52.8M
FUNDAMENTALS RATINGS
ERNA vs PEN vs SLNO: Fundamental Ratings
ERNA
PEN
SLNO
OUTLOOK RATING
1..100
54754
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
95
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
1008249
SMR RATING
1..100
1006298
PRICE GROWTH RATING
1..100
975056
P/E GROWTH RATING
1..100
100100100
SEASONALITY SCORE
1..100
905050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ERNA's Valuation (29) in the Medical Specialties industry is somewhat better than the same rating for SLNO (72) and is significantly better than the same rating for PEN (95). This means that ERNA's stock grew somewhat faster than SLNO’s and significantly faster than PEN’s over the last 12 months.

SLNO's Profit vs Risk Rating (49) in the Medical Specialties industry is somewhat better than the same rating for PEN (82) and is somewhat better than the same rating for ERNA (100). This means that SLNO's stock grew somewhat faster than PEN’s and somewhat faster than ERNA’s over the last 12 months.

PEN's SMR Rating (62) in the Medical Specialties industry is somewhat better than the same rating for SLNO (98) and is somewhat better than the same rating for ERNA (100). This means that PEN's stock grew somewhat faster than SLNO’s and somewhat faster than ERNA’s over the last 12 months.

PEN's Price Growth Rating (50) in the Medical Specialties industry is in the same range as SLNO (56) and is somewhat better than the same rating for ERNA (97). This means that PEN's stock grew similarly to SLNO’s and somewhat faster than ERNA’s over the last 12 months.

PEN's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as SLNO (100) and is in the same range as ERNA (100). This means that PEN's stock grew similarly to SLNO’s and similarly to ERNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ERNAPENSLNO
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
N/A
Bullish Trend 15 days ago
78%
Bullish Trend 7 days ago
87%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 13 days ago
72%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VEVFX45.25N/A
N/A
Vanguard Explorer Value Inv
ICTTX15.21N/A
N/A
ICON Health and Information Tech Inv
JHSGX30.62N/A
N/A
JHancock U.S. Growth R4
RPTIX102.85N/A
N/A
T. Rowe Price Mid-Cap Growth I
COIRX18.66N/A
N/A
Calvert International Opportunities R6